Hansa Biopharma AB (HNSA) — Long-term Investment Intensity
Hansa Biopharma AB (HNSA) has a Long-term Investment Intensity of 9.1% as of March 2019. Long-term investments of Skr81.97 Million represent 9.1% of total assets of Skr898.03 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check how aggressively does Hansa Biopharma AB reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Hansa Biopharma AB Long-term Investment Intensity (2015–2018)
This chart shows how Hansa Biopharma AB's Long-term Investment Intensity has evolved across 4 annual periods from 2015 to 2018. As of March 2019, the intensity stands at 9.1%, reflecting long-term investments of Skr81.97 Million against total assets of Skr898.03 Million SEK. Explore Hansa Biopharma AB (HNSA) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for Hansa Biopharma AB (2015–2018)
The table below presents the year-by-year Long-term Investment Intensity for Hansa Biopharma AB from 2015 to 2018, covering 4 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see Hansa Biopharma AB market capitalisation.
| Year | LT Investment Intensity | LT Investments (SEK) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2018 | 4.2% | Skr39.53 Million | Skr944.82 Million | ▲ +1.5 pp |
| 2017 | 2.7% | Skr18.51 Million | Skr680.41 Million | ▼ -2.0 pp |
| 2016 | 4.7% | Skr14.57 Million | Skr310.67 Million | ▲ +1.4 pp |
| 2015 | 3.3% | Skr7.28 Million | Skr224.09 Million | — |